Genzyme to Feature Multiple Sclerosis Pipeline and Present New Data on Aubagio and Lemtrada at ECTRIMS

Genzyme to Feature Multiple Sclerosis Pipeline and Present New Data on Aubagio and Lemtrada at ECTRIMS

, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that its multiple sclerosis pipeline, which includes a new generation of investigational treatments in early development, will be featured during the 30 Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) being held in Boston Sept. 10-13. The company will also present this week 26 oral and poster presentations from its MS franchise, including four-year results from the Lemtrada™ (alemtuzumab) extension study,12-year MRI data for Aubagio(teriflunomide), and data from the Aubagio TOPIC study, which was recently published in .

In addition to its marketed therapies, Genzyme has an MS R&D pipeline focused on investigational treatments to address unmet needs for relapsing and progressive forms of MS through research in selective immunomodulation, neuroprotection and remyelination.

Key Genzyme MS programs and collaborations in clinical and preclinical development include:

. “.”

Presentations on Aubagio and Lemtrada at ECTRIMS are as follows, along with information about Genzyme-sponsored activities.

Abstracts are available on the ECTRIMS website.

Date: Wednesday, Sept. 10 at 5:30 p.m.

Location: Veteran’s Memorial Auditorium, 2nd floor, Hynes Convention Center

Date: Thursday, Sept. 11 at 9:00 a.m.

Location: Veteran’s Memorial Auditorium, 2nd and 3rd floors, Hynes Convention Center

Genzyme will engage the community in interactive events are intended to bring to life some of the most common symptoms of MS – including vision impairment, cognitive challenges, and fatigue – and help participants better understand some of the challenges that people living with MS may face. For every person who participates in the experience, Genzyme will pledge volunteer hours that will be given back to the MS community. Visit the Prudential Center on Wednesday September 10 and Thursday September 11 to participate in the dynamic experiences.

Aubagio is approved in the United States, European Union, Australia, Argentina, Brazil, Canada, Chile, Columbia, Honduras, Mexico, New Zealand, Russia, South Korea, Switzerland, Turkey and Ukraine, with additional marketing applications under review by regulatory authorities globally.

Aubagio is an immunomodulator with anti-inflammatory properties. Although the exact mechanism of action for Aubagio is not fully understood, it may involve a reduction in the number of activated lymphocytes in the central nervous system (CNS). Aubagio is supported by one of the largest clinical programs of any MS therapy, with more than 5,000 trial participants in 36 countries. Some patients in extension trials have been treated for up to 10 years.

Lemtrada is approved in the European Union, Australia, Canada, Mexico, Brazil, Argentina, Chile and Guatemala. Lemtrada is currently not approved in the United States. The U.S. Food and Drug Administration (FDA) has accepted for review the company’s resubmission of its application seeking approval of Lemtrada, and Genzyme expects FDA action on the application in the fourth quarter. Marketing applications for Lemtrada are also under review in other countries. Lemtrada is supported by a comprehensive and extensive clinical development program that involved nearly 1,500 patients and 5,400 patient-years of follow-up.

Alemtuzumab is a monoclonal antibody that selectively targets CD52, a protein abundant on T and B cells. Treatment with alemtuzumab results in the depletion of circulating T and B cells thought to be responsible for the damaging inflammatory process in MS. Alemtuzumab has minimal impact on other immune cells. The acute anti-inflammatory effect of alemtuzumab is immediately followed by the onset of a distinctive pattern of T and B cell repopulation that continues over time, rebalancing the immune system in a way that potentially reduces MS disease activity.

Genzyme holds the worldwide rights to alemtuzumab and has primary responsibility for its development and commercialization in multiple sclerosis. Bayer HealthCare holds the right to co-promote alemtuzumab in MS in the United States. Upon commercialization, Bayer will receive contingent payments based on global sales revenue.

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at .

Genzyme and Aubagio are registered trademarks and Lemtrada is a trademark of Genzyme Corporation.

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Read more on